Kano Therapeutics develops genetic payloads using circular single-stranded DNA (ssDNA) for the targeted correction of long stretches of DNA. This novel ssDNA biomaterial offers precise, safe insertion capabilities that complement existing gene editing tools like CRISPR. Their fermentation-based production method enables cost-effective manufacturing of these optimized DNA donor templates for genomic engineering applications.
Funding
$7.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing gene editing tools often struggle with efficient and precise insertion of long DNA sequences, leading to off-target effects and limiting their potential for complete genetic cures. The delivery of large DNA payloads can also trigger unwanted immune responses, further complicating therapeutic applications.
Solution
Kano Therapeutics is developing circular single-stranded DNA (ssDNA) templates produced through a fermentation-based method. This approach enables precise, gene-length DNA insertion with improved efficiency and reduced off-target effects compared to traditional methods. By focusing on optimized DNA donor material, Kano's technology aims to provide a safer and more effective means for genomic engineering, facilitating the transition from gene editing to complete genetic cures. The use of ssDNA combines the stability of double-stranded DNA with the flexibility of RNA, offering an improved building block for therapeutic nucleic acids. Their DNA donors are designed to complement CRISPR or other gene editing tools used to insert synthetic genes.
Target Audience
Kano Therapeutics targets researchers and companies involved in gene editing and gene therapy, particularly those seeking improved methods for precise and efficient DNA insertion.
Features
- Circular ssDNA templates for precise gene-length DNA insertion
- Fermentation-based production method for cost-effective manufacturing at scale
- Higher site-specific knock-in efficiencies and lower off-target insertion compared to traditional methods
- Reduced DNA payload for the same molar concentration, leading to lower immune activation
- Engineerable, functional 2D/3D features due to the structural flexibility of ssDNA
- A databank linking ssDNA sequence design to activity, speeding up development timelines